BL_Tier2.md
... ...
@@ -1,76 +1,80 @@
1
-### *72 total*
2 1
3
-|Gene|Summary| First BL study | Other entities | QC result |
4
-|:-:|:--:|:-:|:-|:-|
5
-|[ADAMTS5](ADAMTS5)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
6
-|[ADNP](ADNP)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
7
-|[AGO4](AGO4)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
8
-|[ARHGEF1](ARHGEF1)|Tier 2 GE[@muppidiLossSignalingGa132014]|[Muppidi et al](papers/muppidiLossSignalingGa132014)|||
9
-|[BCL2](BCL2)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022], aSHM|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|[@morinFrequentMutationHistonemodifying2011; @sarkozyMutationalLandscapeGray2021; @tanakaFrequentIncidenceSomatic1992]||
10
-|[BTG1](BTG1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022], FE[@almasmoumFrequentLossBTG12021], aSHM|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|[@drevalGeneticSubdivisionsFollicular2023; @morinFrequentMutationHistonemodifying2011; @sarkozyMutationalLandscapeGray2021]||
11
-|[C16orf48](C16orf48)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
12
-|[CARD4](CARD4)|Tier 2 GE[@loveGeneticLandscapeMutations2012]|[Love et al](papers/loveGeneticLandscapeMutations2012)||PASS|
13
-|[CCNF](CCNF)|Tier 2 GE[@abateDistinctViralMutational2015]|[Abate et al](papers/abateDistinctViralMutational2015)|[@zhangGeneticHeterogeneityDiffuse2013]||
14
-|[CD79A](CD79A)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|[@rossiCodingGenomeSplenic2012]||
15
-|[CD83](CD83)|Tier 2 GE[@paneaWholeGenomeLandscape2019], aSHM|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@dunsCharacterizationDLBCLPMBL2021; @morinMutationalStructuralAnalysis2013; @russler-germainMutationsAssociatedProgression2023]|PASS|
16
-|[CDC73](CDC73)|Tier 2 GE[@loveGeneticLandscapeMutations2012]|[Love et al](papers/loveGeneticLandscapeMutations2012)|[@reddyGeneticFunctionalDrivers2017]|PASS|
17
-|[CDKN2A](CDKN2A)|Tier 2 GE[@grandeGenomewideDiscoverySomatic2019], FE[@kannengiesserFunctionalStructuralGenetic2009]|[Grande et al](papers/grandeGenomewideDiscoverySomatic2019)|[@morinMutationalStructuralAnalysis2013; @spinaGeneticsNodalMarginal2016]||
18
-|[CDKN2C](CDKN2C)|Tier 2 GE[@thomasGeneticSubgroupsInform2023]|[Thomas et al](papers/thomasGeneticSubgroupsInform2023)|||
19
-|[CHD4](CHD4)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
20
-|[CPXM2](CPXM2)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
21
-|[CXCR4](CXCR4)|Tier 2 GE[@paneaWholeGenomeLandscape2019], FE[@zmajkovicovaGenotypephenotypeCorrelationsWHIM2022], aSHM|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@khodabakhshiRecurrentTargetsAberrant2012; @krysiakRecurrentSomaticMutations2017]|PASS|
22
-|[DHCR7](DHCR7)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
23
-|[E2F2](E2F2)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
24
-|[EBF1](EBF1)|Tier 2 GE[@thomasGeneticSubgroupsInform2023], FE[@ramirez-komoSpontaneousLossLineage2017], aSHM|[Thomas et al](papers/thomasGeneticSubgroupsInform2023)|[@bohleRoleEarlyBcell2013; @drevalGeneticSubdivisionsFollicular2023; @reichelFlowSortingExome2015]||
25
-|[EDNRB](EDNRB)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
26
-|[EHD1](EHD1)|Tier 2 GE[@thomasGeneticSubgroupsInform2023]|[Thomas et al](papers/thomasGeneticSubgroupsInform2023)|||
27
-|[EIF4A1](EIF4A1)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|||
28
-|[ELP2](ELP2)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
29
-|[EPPK1](EPPK1)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|||
30
-|[ERAP1](ERAP1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
31
-|[EXOSC6](EXOSC6)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
32
-|[EZH2](EZH2)|Tier 2 GE[@loveGeneticLandscapeMutations2012], FE[@sneeringerCoordinatedActivitiesWildtype2010]|[Love et al](papers/loveGeneticLandscapeMutations2012)|[@morinSomaticMutationsAltering2010; @mottokIntegrativeGenomicAnalysis2019]|PASS|
33
-|[FLYWCH1](FLYWCH1)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
34
-|[GGTLA4](GGTLA4)|Tier 2 GE[@loveGeneticLandscapeMutations2012]|[Love et al](papers/loveGeneticLandscapeMutations2012)||PASS|
35
-|[GTSE1](GTSE1)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
36
-|[HIST1H3D](HIST1H3D)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)||PASS|
37
-|[HIST1H3I](HIST1H3I)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@krysiakRecurrentSomaticMutations2017]|PASS|
38
-|[HIST1H4J](HIST1H4J)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@mottokIntegrativeGenomicAnalysis2019]|PASS|
39
-|[HLA-DQB1](HLA-DQB1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
40
-|[IGLL5](IGLL5)|Tier 2 GE[@paneaWholeGenomeLandscape2019], aSHM|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@chapuyMolecularSubtypesDiffuse2018; @deschGenotypingCirculatingTumor2020; @russler-germainMutationsAssociatedProgression2023]|PASS|
41
-|[IKZF3](IKZF3)|Tier 2 GE[@paneaWholeGenomeLandscape2019], FE[@lazarianHotspotMutationTranscription2021]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@morinFrequentMutationHistonemodifying2011]|PASS|
42
-|[IRF8](IRF8)|Tier 2 GE[@paneaWholeGenomeLandscape2019], FE[@qiuIRF8mutantCellLymphoma2024], aSHM|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@morinFrequentMutationHistonemodifying2011; @mottokIntegrativeGenomicAnalysis2019]|PASS|
43
-|[KANK2](KANK2)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
44
-|[KLHL26](KLHL26)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
45
-|[KMT2C](KMT2C)|Tier 2 GE[@zhouSporadicEndemicBurkitt2019]|[Zhou et al](papers/zhouSporadicEndemicBurkitt2019)|[@sarkozyMutationalLandscapeGray2021; @zhangGeneticHeterogeneityDiffuse2013; @zhangGenomicLandscapeMantle2014]||
46
-|[MCL1](MCL1)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@dunsCharacterizationDLBCLPMBL2021; @reddyGeneticFunctionalDrivers2017]|PASS|
47
-|[MIR142](MIR142)|Tier 2 GE[@grandeGenomewideDiscoverySomatic2019], FE[@trissalMIR142LossofFunctionMutations2018], aSHM|[Grande et al](papers/grandeGenomewideDiscoverySomatic2019)|[@kwanhianMicroRNA142Mutated202012]||
48
-|[MKI67](MKI67)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|[@russler-germainMutationsAssociatedProgression2023]||
49
-|[MYO18A](MYO18A)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
50
-|[NBEAL1](NBEAL1)|Tier 2 GE[@loveGeneticLandscapeMutations2012]|[Love et al](papers/loveGeneticLandscapeMutations2012)||PASS|
51
-|[NCOR2](NCOR2)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|[@sarkozyMutationalLandscapeGray2021; @spinaGeneticsNodalMarginal2016]||
52
-|[NOA1](NOA1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
53
-|[P2RY2](P2RY2)|Tier 2 GE[@loveGeneticLandscapeMutations2012]|[Love et al](papers/loveGeneticLandscapeMutations2012)||PASS|
54
-|[PDCD11](PDCD11)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
55
-|[PIM1](PIM1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022], FE[@kuoRolePIM1Ibrutinibresistant2016], aSHM|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|[@drevalGeneticSubdivisionsFollicular2023; @dunsCharacterizationDLBCLPMBL2021; @pasqualucciHypermutationMultipleProtooncogenes2001]||
56
-|[PLCG2](PLCG2)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@fanComprehensiveCharacterizationDriver2020]|PASS|
57
-|[PPP6R2](PPP6R2)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
58
-|[PREX1](PREX1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
59
-|[RANBP6](RANBP6)|Tier 2 GE[@loveGeneticLandscapeMutations2012]|[Love et al](papers/loveGeneticLandscapeMutations2012)||PASS|
60
-|[REV3L](REV3L)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
61
-|[RNF144B](RNF144B)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)||PASS|
62
-|[RPL10](RPL10)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
63
-|[S1PR2](S1PR2)|Tier 2 GE[@muppidiLossSignalingGa132014], FE[@muppidiLossSignalingGa132014], aSHM|[Muppidi et al](papers/muppidiLossSignalingGa132014)|[@drevalGeneticSubdivisionsFollicular2023; @morinFrequentMutationHistonemodifying2011]||
64
-|[SAL3](SAL3)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
65
-|[TET2](TET2)|Tier 2 GE[@thomasGeneticSubgroupsInform2023], FE[@asmarGenomewideProfilingIdentifies2013]|[Thomas et al](papers/thomasGeneticSubgroupsInform2023)|[@albuquerqueEnhancingKnowledgeDiscovery2017]||
66
-|[TOP2A](TOP2A)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
67
-|[TTN](TTN)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
68
-|[VWA7](VWA7)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
69
-|[WDR90](WDR90)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
70
-|[WHAMM](WHAMM)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
71
-|[WNK2](WNK2)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)||PASS|
72
-|[YY1AP1](YY1AP1)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
73
-|[ZAN](ZAN)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
74
-|[ZBTB7A](ZBTB7A)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|[@reddyGeneticFunctionalDrivers2017]||
75
-|[ZFP36L1](ZFP36L1)|Tier 2 GE[@paneaWholeGenomeLandscape2019], aSHM|[Panea et al](papers/paneaWholeGenomeLandscape2019)|[@morinFrequentMutationHistonemodifying2011; @reichelFlowSortingExome2015]|PASS|
76
-|[ZNF85](ZNF85)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|||
2
+|Gene|Status| First BL study |
3
+|:-:|:--:|:-:|
4
+|[ADAMTS5](ADAMTS5)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
5
+|[ADNP](ADNP)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
6
+|[AGO4](AGO4)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
7
+|[ARHGEF1](ARHGEF1)|Tier 2|[Muppidi et al](papers/muppidiLossSignalingGa132014)|
8
+|[B2M](B2M)|Tier 2|[Ma et al](papers/maSubtypespecificCooccurringGenetic2022)|
9
+|[BCL2](BCL2)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
10
+|[BTG1](BTG1)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
11
+|[C16orf48](C16orf48)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
12
+|[CARD11](CARD11)|Tier 2|[Ma et al](papers/maSubtypespecificCooccurringGenetic2022)|
13
+|[CARD4](CARD4)|Tier 2|[Love et al](papers/loveGeneticLandscapeMutations2012)|
14
+|[CCNF](CCNF)|Tier 2|[Abate et al](papers/abateDistinctViralMutational2015)|
15
+|[CD79A](CD79A)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
16
+|[CD83](CD83)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
17
+|[CDC27](CDC27)|Tier 2|[Ma et al](papers/maSubtypespecificCooccurringGenetic2022)|
18
+|[CDC73](CDC73)|Tier 2|[Love et al](papers/loveGeneticLandscapeMutations2012)|
19
+|[CDKN2A](CDKN2A)|Tier 2|[Grande et al](papers/grandeGenomewideDiscoverySomatic2019)|
20
+|[CDKN2C](CDKN2C)|Tier 2|[Thomas et al](papers/thomasGeneticSubgroupsInform2023)|
21
+|[CHD4](CHD4)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
22
+|[CPXM2](CPXM2)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
23
+|[CXCR4](CXCR4)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
24
+|[DHCR7](DHCR7)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
25
+|[E2F2](E2F2)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
26
+|[EBF1](EBF1)|Tier 2|[Thomas et al](papers/thomasGeneticSubgroupsInform2023)|
27
+|[EDNRB](EDNRB)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
28
+|[EHD1](EHD1)|Tier 2|[Thomas et al](papers/thomasGeneticSubgroupsInform2023)|
29
+|[EIF4A1](EIF4A1)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
30
+|[ELP2](ELP2)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
31
+|[EPPK1](EPPK1)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
32
+|[ERAP1](ERAP1)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
33
+|[EXOSC6](EXOSC6)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
34
+|[FLYWCH1](FLYWCH1)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
35
+|[GGTLA4](GGTLA4)|Tier 2|[Love et al](papers/loveGeneticLandscapeMutations2012)|
36
+|[GTSE1](GTSE1)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
37
+|[HIST1H1B](HIST1H1B)|Tier 2|[Ma et al](papers/maSubtypespecificCooccurringGenetic2022)|
38
+|[HIST1H3D](HIST1H3D)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
39
+|[HIST1H3I](HIST1H3I)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
40
+|[HIST1H4J](HIST1H4J)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
41
+|[HLA-DQB1](HLA-DQB1)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
42
+|[IKZF3](IKZF3)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
43
+|[IRF8](IRF8)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
44
+|[KANK2](KANK2)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
45
+|[KLHL26](KLHL26)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
46
+|[KMT2C](KMT2C)|Tier 2|[Zhou et al](papers/zhouSporadicEndemicBurkitt2019)|
47
+|[MCL1](MCL1)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
48
+|[MIR142](MIR142)|Tier 2|[Grande et al](papers/grandeGenomewideDiscoverySomatic2019)|
49
+|[MKI67](MKI67)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
50
+|[MYO18A](MYO18A)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
51
+|[NBEAL1](NBEAL1)|Tier 2|[Love et al](papers/loveGeneticLandscapeMutations2012)|
52
+|[NCOR2](NCOR2)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
53
+|[NOA1](NOA1)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
54
+|[P2RY2](P2RY2)|Tier 2|[Love et al](papers/loveGeneticLandscapeMutations2012)|
55
+|[PDCD11](PDCD11)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
56
+|[PIM1](PIM1)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
57
+|[PLCG2](PLCG2)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
58
+|[PPP6R2](PPP6R2)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
59
+|[PRDM1](PRDM1)|Tier 2|[Ma et al](papers/maSubtypespecificCooccurringGenetic2022)|
60
+|[PREX1](PREX1)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
61
+|[RANBP6](RANBP6)|Tier 2|[Love et al](papers/loveGeneticLandscapeMutations2012)|
62
+|[REV3L](REV3L)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
63
+|[RNF144B](RNF144B)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
64
+|[RPL10](RPL10)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
65
+|[S1PR2](S1PR2)|Tier 2|[Muppidi et al](papers/muppidiLossSignalingGa132014)|
66
+|[SAL3](SAL3)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
67
+|[TBL1XR1](TBL1XR1)|Tier 2|[Ma et al](papers/maSubtypespecificCooccurringGenetic2022)|
68
+|[TET2](TET2)|Tier 2|[Thomas et al](papers/thomasGeneticSubgroupsInform2023)|
69
+|[TNFRSF14](TNFRSF14)|Tier 2|[Ma et al](papers/maSubtypespecificCooccurringGenetic2022)|
70
+|[TOP2A](TOP2A)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
71
+|[TTN](TTN)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
72
+|[VWA7](VWA7)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
73
+|[WDR90](WDR90)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
74
+|[WHAMM](WHAMM)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
75
+|[WNK2](WNK2)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
76
+|[YY1AP1](YY1AP1)|Tier 2|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|
77
+|[ZAN](ZAN)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
78
+|[ZBTB7A](ZBTB7A)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
79
+|[ZFP36L1](ZFP36L1)|Tier 2|[Panea et al](papers/paneaWholeGenomeLandscape2019)|
80
+|[ZNF85](ZNF85)|Tier 2|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022)|
... ...
\ No newline at end of file